Long-term Extension Study of Ligelizumab in Food Allergy
|
Food Allergy |
Phase 3 |
United States |
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
|
Macular Polypoidal Choroidal Vasculopathy (PCV) |
Phase 3 |
Korea, Republic of |
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
|
Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Phase 2 |
China |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
|
Primary Immune Thrombocytopenia (ITP) |
Phase 3 |
United States Spain Czech RepublicBelgium Romania Hungary France Germany Japan Norway Hong Kong Malaysia Australia Singapore United Kingdom View All |
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
|
Primary Immune Thrombocytopenia |
Phase 3 |
United States Turkey SpainChina Czech Republic Hungary Germany Norway Korea, Republic of Malaysia Austria United Kingdom Japan Belgium Singapore Netherlands View All |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
|
Warm Autoimmune Hemolytic Anemia (wAIHA) |
Phase 3 |
Italy Thailand SpainFrance Romania Hungary Germany China Japan Malaysia United Kingdom Australia Singapore View All |
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
|
Systemic Lupus Erythematosus |
Phase 3 |
Spain China United StatesJapan Hungary View All |
Kesimpta (Ofatumumab) Pregnancy Registry
|
Multiple Sclerosis, Pregnancy |
|
United States |
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
|
Advanced Breast Cancer |
Phase 4 |
India |
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
|
Paroxysmal Nocturnal Hemoglobinuria |
Phase 3 |
United States |